409 related articles for article (PubMed ID: 18955518)
1. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
[TBL] [Abstract][Full Text] [Related]
2. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
[TBL] [Abstract][Full Text] [Related]
3. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
[TBL] [Abstract][Full Text] [Related]
4. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.
Ide K; Aoki M; Amano M; Koh Y; Yedidi RS; Das D; Leschenko S; Chapsal B; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2011 Apr; 55(4):1717-27. PubMed ID: 21282450
[TBL] [Abstract][Full Text] [Related]
5. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
[TBL] [Abstract][Full Text] [Related]
6. Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Tojo Y; Koh Y; Amano M; Aoki M; Das D; Kulkarni S; Anderson DD; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2010 Aug; 54(8):3460-70. PubMed ID: 20439612
[TBL] [Abstract][Full Text] [Related]
7. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
Koh Y; Nakata H; Maeda K; Ogata H; Bilcer G; Devasamudram T; Kincaid JF; Boross P; Wang YF; Tie Y; Volarath P; Gaddis L; Harrison RW; Weber IT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2003 Oct; 47(10):3123-9. PubMed ID: 14506019
[TBL] [Abstract][Full Text] [Related]
8. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
[TBL] [Abstract][Full Text] [Related]
9. A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.
Amano M; Tojo Y; Salcedo-Gómez PM; Parham GL; Nyalapatla PR; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2015 May; 59(5):2625-35. PubMed ID: 25691652
[TBL] [Abstract][Full Text] [Related]
10. GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
Salcedo Gómez PM; Amano M; Yashchuk S; Mizuno A; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 Dec; 57(12):6110-21. PubMed ID: 24080647
[TBL] [Abstract][Full Text] [Related]
11. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
[TBL] [Abstract][Full Text] [Related]
12. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
Dandache S; Sévigny G; Yelle J; Stranix BR; Parkin N; Schapiro JM; Wainberg MA; Wu JJ
Antimicrob Agents Chemother; 2007 Nov; 51(11):4036-43. PubMed ID: 17638694
[TBL] [Abstract][Full Text] [Related]
13. GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro.
Amano M; Miguel Salcedo-Gómez P; Yedidi RS; Delino NS; Nakata H; Venkateswara Rao K; Ghosh AK; Mitsuya H
Sci Rep; 2017 Sep; 7(1):12235. PubMed ID: 28947797
[TBL] [Abstract][Full Text] [Related]
14. Novel Protease Inhibitors Containing C-5-Modified
Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
[TBL] [Abstract][Full Text] [Related]
15. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
Prado JG; Wrin T; Beauchaine J; Ruiz L; Petropoulos CJ; Frost SD; Clotet B; D'Aquila RT; Martinez-Picado J
AIDS; 2002 May; 16(7):1009-17. PubMed ID: 11953467
[TBL] [Abstract][Full Text] [Related]
16. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
[TBL] [Abstract][Full Text] [Related]
17. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.
Yoshimura K; Kato R; Kavlick MF; Nguyen A; Maroun V; Maeda K; Hussain KA; Ghosh AK; Gulnik SV; Erickson JW; Mitsuya H
J Virol; 2002 Feb; 76(3):1349-58. PubMed ID: 11773409
[TBL] [Abstract][Full Text] [Related]
18. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.
Carrillo A; Stewart KD; Sham HL; Norbeck DW; Kohlbrenner WE; Leonard JM; Kempf DJ; Molla A
J Virol; 1998 Sep; 72(9):7532-41. PubMed ID: 9696850
[TBL] [Abstract][Full Text] [Related]
19. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
[TBL] [Abstract][Full Text] [Related]
20. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
